SCHEMBL3552895

SCHEMBL3552895

NC(=O)c1cc(Oc2ccc(N(C(=O)C3(C(N)=O)CC3)c3ccc(F)cc3)c(F)c2F)ccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 10/20 0.37
AXL P30530 7/20 0.37
MERTK Q12866 5/20 0.37
SCN9A Q15858 3/20 0.34
KDR P35968 3/20 0.34
NTRK1 P04629 2/20 0.34
TEK Q02763 2/20 0.34
NTRK3 Q16288 1/20 0.34
NTRK2 Q16620 1/20 0.34
P2RX3 P56373 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
RIPK1 Q13546 1/20 0.33
AURKA O14965 1/20 0.33
RIPK2 O43353 1/20 0.33
ABCB11 O95342 1/20 0.33
ABL1 P00519 1/20 0.33
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
LCK P06239 1/20 0.33
PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3553741 0.90 MET (0.43) METAXLMERTKKDRNTRK1
SCHEMBL1728030 0.87 MET (0.41) METAXLMERTKSCN9AKDR
SCHEMBL3494015 0.84 AXL (0.47) METAXLKDRKITFLT3
SCHEMBL3620026 0.82 MET (0.40) METAXLMERTKKDRNTRK1
SCHEMBL3559224 0.79 MET (0.39) METAXLMERTKKDRNTRK1
SCHEMBL1137371 0.78 MET (0.41) METAXLMERTKKDRNTRK1
SCHEMBL2410939 0.77 CSF1R (0.47) METAXLKDRKITFLT3
SCHEMBL139115 0.77 MET (0.46) METAXLMERTKKDRNTRK1
SCHEMBL3556668 0.77 MET (0.52) METAXLMERTKKDRNTRK1
SCHEMBL139146 0.77 MET (0.41) METAXLMERTKSCN9AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1889836-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) EISAI R&D MAN CO LTD (JP) 2013-06-12 EP disclosed
US-8288538-B2 Pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-10-16 US disclosed
US-7855290-B2 N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-21 US disclosed
US-20100075944-A1 NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) MATSUSHIMA TOMOHIRO 2010-03-25 US disclosed
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-12-25 US disclosed
EP-1889836-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) Eisai R&D Management Co., Ltd. (JP) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) HGF, MET, FLT4 MET 2/4885AXL 88/4885MERTK 2515/4885
US-20100075944-A1 NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) HGF, MET, HDGF MET 2/4885AXL 100/4885MERTK 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.